HUADONG MEDICINE CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.5 CNY | -0.06% |
|
+8.62% | -24.02% |
| Apr. 18 | Huadong Medicine's 2023 Profit Jumps 14% | MT |
| Apr. 17 | Huadong Medicine Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | 44.88B 6.2B | Sales 2025 * | 50.02B 6.91B | Capitalization | 55.13B 7.61B |
|---|---|---|---|---|---|
| Net income 2024 * | 3.38B 467M | Net income 2025 * | 4.22B 583M | EV / Sales 2024 * | 1.13 x |
| Net cash position 2024 * | 4.28B 591M | Net cash position 2025 * | 6.01B 830M | EV / Sales 2025 * | 0.98 x |
| P/E ratio 2024 * |
16.3
x | P/E ratio 2025 * |
13.1
x | Employees | 14,061 |
| Yield 2024 * |
1.56% | Yield 2025 * |
1.87% | Free-Float | 41.75% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.06% | ||
| 1 week | +8.62% | ||
| Current month | +1.61% | ||
| 1 month | -5.58% | ||
| 3 months | -8.59% | ||
| 6 months | -23.04% | ||
| Current year | -24.02% |
1 week
29.05
31.97
1 month
28.9033.48
Current year
27.6041.45
1 year
27.6046.43
3 years
27.6053.94
5 years
16.0253.94
10 years
11.6753.94
| Managers | Title | Age | Since |
|---|---|---|---|
Hong Lan Ma
DFI | Director of Finance/CFO | 53 | - |
Bang Liang Li
CHM | Chairman | 78 | 71-12-31 |
Dong Zhou Liu
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bang Liang Li
CHM | Chairman | 78 | 71-12-31 |
Wei Kang
BRD | Director/Board Member | 56 | - |
Liang Lü
CEO | Chief Executive Officer | 50 | 10-03-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.41% | 2 M€ | -20.87% | - | |
| 0.99% | 2 M€ | -14.14% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 31.5 | -0.06% | 14,301,360 |
| 24-04-18 | 31.52 | +4.89% | 27,738,660 |
| 24-04-17 | 30.05 | +1.90% | 12,517,050 |
| 24-04-16 | 29.49 | -0.03% | 11,278,550 |
| 24-04-15 | 29.5 | +1.72% | 10,756,690 |
End-of-day quote Shenzhen S.E., April 18, 2024
More quotes
Huadong Medicine Co., Ltd. specializes in the development, manufacture and marketing of medical products and vaccines. The products are intended primarily for the treatment of tumors, immune disorders, endocrine disorders, orthopedic and traumatological disorders, digestive system diseases and viral diseases.
Sector
Pharmaceuticals
Calendar
2024-04-25
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
31.5
CNY
Average target price
48.81
CNY
Spread / Average Target
+54.96%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -24.02% | 7.62B | |
| +13.36% | 68.18B | |
| +7.33% | 25.78B | |
| +6.34% | 7.99B | |
| -2.79% | 7.88B | |
| +21.83% | 4.45B | |
| -2.28% | 3.89B | |
| -3.51% | 3.82B | |
| +25.02% | 3.69B | |
| +3.28% | 3.24B |
- Stock Market
- Equities
- 000963 Stock
